Rapid exacerbation of neuromyelitis optica after rituximab treatment
- PMID: 26704780
- DOI: 10.1016/j.jocn.2015.08.033
Rapid exacerbation of neuromyelitis optica after rituximab treatment
Abstract
Studies have shown the efficacy of immunosuppressants against neuromyelitis optica (NMO). Rituximab is recommended as an off-label prescription to treat refractory NMO. However, we describe two such patients who were suboptimally responsive to rituximab and whose symptoms worsened after treatment. Our cautionary cases highlight that in a small proportion of patients with refractory NMO, rituximab may either fail or induce rapid relapse of NMO. This suggests we need to consider new treatment strategies for refractory NMO.
Keywords: Neuromyelitis optica; Relapse; Rituximab; Therapy.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources